Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Key facts

Sponsor

Cure HHT

Principal Investigator

Melissa A Dickey, MSN, FNP

Cure HHT

Enrollment

10000 enrolled

Eligibility

All sexes

Timeline

2023 – 2033

Study locations (16)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• University of California, Los Angeles, Los Angeles, California, United States
• University of California, San Francisco, San Francisco, California, United States
• University of Colorado, Denver, Aurora, Colorado, United States
• Yale University, New Haven, Connecticut, United States
• Augusta University, Augusta, Georgia, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Columbia University, New York, New York, United States
• University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States
• The Cleveland Clinic, Cleveland, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• University of Texas Southwestern, Dallas, Texas, United States
• +1 more locations on ClinicalTrials.gov

Collaborators

Augusta University · The Cleveland Clinic · Mayo Clinic · Massachusetts General Hospital · Columbia University · Oregon Health and Science University · University of California, Los Angeles · University of California, San Francisco · University of Colorado, Denver · University of North Carolina, Chapel Hill · University of Pennsylvania · University of Texas · University of Utah · Washington University School of Medicine · Yale University · Health Resources and Services Administration (HRSA) · University of Alabama at Birmingham

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Brain arteriovenous malformation

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07519876
  Pulmonary Embolism and Right-to-Left Shunts
  Tufts Medical Center
• RECRUITINGPHASE2, PHASE3NCT06264531
  Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
  Fondation Ophtalmologique Adolphe de Rothschild
• RECRUITINGNCT07118631
  Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding
  Beijing Tiantan Hospital
• RECRUITINGPHASE2NCT06913725
  An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
  Xuanwu Hospital, Beijing
• RECRUITINGNANCT07314047
  The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation
  MicroPort NeuroTech Co., Ltd.
• RECRUITINGNCT05449106
  Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT
  Beijing Tiantan Hospital
• RECRUITINGNCT04927156
  Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
  Balt Extrusion
• RECRUITINGNCT03676868
  Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
  Fondation Ophtalmologique Adolphe de Rothschild

See all trials for Brain arteriovenous malformation →